GlassScriptPhysician profile
Federico L Rivas Gotz
NPI 1053354092
$2,210.72
in general payments reported to CMS, 2019-2025
25 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $430 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $313.51 | 2019-2025 | Airsupra |
| Pfizer INC. | $244.56 | 2019-2025 | |
| Amgen INC. | $218.80 | 2019-2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $147.11 | 2019-2020 | |
| Astellas Pharma US INC | $124.14 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $120.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $117.54 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.96 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $75.92 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.32 | 2019 | |
| Allergan, INC. | $71.80 | 2019-2020 | |
| Novo Nordisk INC | $62.40 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $61.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.45 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.48 | 2019-2020 | |
| Lilly USA, LLC | $37.65 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $24.56 | 2019 | |
| Pulmonx Corporation | $18.78 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2025 | |
| Scilex Pharmaceuticals INC. | $13.86 | 2019 | |
| Eisai INC. | $12.92 | 2019 | |
| Nabriva Therapeutics, Plc | $12.86 | 2020 | |
| Mylan Specialty L.P. | $11.84 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Rivas Gotz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.